Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20250101 - 20251231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 25101699 |
US |
||
Malignant neoplasm progression, Hepatotoxicity, Drug ineffective, |
||||
ABEMACICLIB, |
||||
| 202 | 25101700 |
FR |
63 | 1 |
Respiratory distress, Malignant neoplasm progression, Pneumothorax, |
||||
PEMETREXED DISODIUM, AMIVANTAMAB, CARBOPLATIN, OSIMERTINIB, |
||||
| 203 | 25101925 |
JP |
70 | 2 |
Malignant neoplasm progression, Intestinal perforation, Abscess intestinal, |
||||
PEMBROLIZUMAB, |
||||
| 204 | 25101954 |
FR |
63 | 1 |
Respiratory distress, Non-small cell lung cancer, Malignant neoplasm progression, Pneumothorax, |
||||
CARBOPLATIN, AMIVANTAMAB, PEMETREXED DISODIUM, OSIMERTINIB, |
||||
| 205 | 25101957 |
PL |
60 | 1 |
Pulmonary embolism, Cough, Pyrexia, Urinary tract infection, Pulmonary tuberculosis, Metastases to lung, Malignant melanoma, Malignant neoplasm progression, Metastases to central nervous system, Urinary retention, Pyrexia, Fatigue, Dizziness, Headache, Diarrhoea, Vomiting, Inflammatory marker increased, |
||||
DABRAFENIB, DABRAFENIB, TRAMETINIB, TRAMETINIB, NIVOLUMAB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 206 | 25101966 |
CN |
52 | 2 |
HER2 positive breast cancer, Malignant neoplasm progression, Metastases to liver, Metastases to central nervous system, Metastases to bone, Metastases to lung, Atelectasis, |
||||
LETROZOLE, LETROZOLE TABLETS, TRASTUZUMAB, PERTUZUMAB, |
||||
| 207 | 25104321 |
79 | 1 | |
Malignant neoplasm progression, |
||||
CAPECITABINE, CAPECITABINE, |
||||
| 208 | 25092613 |
US |
||
Malignant neoplasm progression, |
||||
ABEMACICLIB, FULVESTRANT, DENOSUMAB, |
||||
| 209 | 25093341 |
CA |
72 | 2 |
Malignant neoplasm progression, Transitional cell carcinoma metastatic, Fatigue, Dysphagia, Condition aggravated, Throat irritation, Hyperhidrosis, Pyrexia, Blood pressure fluctuation, Nausea, Diarrhoea, Oxygen saturation decreased, Constipation, Back pain, Abdominal pain, Erythema, Ear pain, Rash, Pain, Dry eye, Dry mouth, Dyspnoea, Chest pain, Vomiting, |
||||
ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, PEMBROLIZUMAB, CITALOPRAM, CITALOPRAM HYDROBROMIDE, PANTOPRAZOLE, |
||||
| 210 | 25093641 |
DE |
68 | 1 |
Malignant neoplasm progression, Off label use, |
||||
CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, IPILIMUMAB, IPILIMUMAB, IPILIMUMAB, IPILIMUMAB, |
||||
| 211 | 25093856 |
PR |
50 | 1 |
Pleural effusion, Malignant neoplasm progression, |
||||
CABOZANTINIB, NIVOLUMAB, METOPROLOL TARTRATE, METOPROLOL, BETAMETHASONE DIPROPIONATE, |
||||
| 212 | 25094161 |
US |
51 | |
Malignant neoplasm progression, |
||||
AZACITIDINE, |
||||
| 213 | 25094217 |
JP |
||
Neuroendocrine tumour of the lung, Malignant neoplasm progression, |
||||
EVEROLIMUS, |
||||
| 214 | 25094285 |
GB |
||
Malignant neoplasm progression, Malignant transformation, |
||||
OSIMERTINIB, |
||||
| 215 | 25094431 |
CA |
39 | 2 |
Asthenia, Drug ineffective, Dysphonia, Fatigue, Hypersomnia, Ill-defined disorder, Illness, Malignant neoplasm progression, Metastases to lung, Metastases to the mediastinum, Nausea, Pleural effusion, |
||||
CAPECITABINE, CAPECITABINE, LETROZOLE, LETROZOLE, LETROZOLE, LETROZOLE, RIBOCICLIB, RIBOCICLIB, GOSERELIN, GOSERELIN, |
||||
| 216 | 25094438 |
CA |
64 | 2 |
Malignant neoplasm progression, Pneumonitis, Product use issue, Therapy partial responder, |
||||
CAPECITABINE, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 217 | 25094544 |
CA |
51 | 2 |
Breast cancer, Malignant neoplasm progression, Metastases to liver, Drug intolerance, Hot flush, Metastases to central nervous system, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, FULVESTRANT, PALBOCICLIB, EVEROLIMUS, LETROZOLE, LETROZOLE TABLETS, RUXOLITINIB, |
||||
| 218 | 25094622 |
US |
2 | |
Non-small cell lung cancer metastatic, Malignant neoplasm progression, Metastases to bone, Hypercalcaemia, |
||||
LORLATINIB, |
||||
| 219 | 25094728 |
JP |
72 | 2 |
Malignant neoplasm progression, Stress cardiomyopathy, Immune-mediated myocarditis, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PEMETREXED DISODIUM, PEMETREXED, |
||||
| 220 | 25095017 |
IN |
22 | 1 |
Malignant neoplasm progression, Chest pain, |
||||
INOTUZUMAB OZOGAMICIN, |
||||
| 221 | 25095133 |
JP |
41 | 2 |
Premature baby, Malignant neoplasm progression, Maternal exposure during pregnancy, Constipation, Nausea, Alopecia, Anaemia, |
||||
GEMCITABINE HYDROCHLORIDE, CISPLATIN, |
||||
| 222 | 25095525 |
RU |
57 | 2 |
Malignant neoplasm progression, Hepatitis, Thrombocytopenia, Off label use, |
||||
| 223 | 25095853 |
TH |
85 | 1 |
Death, Pulmonary embolism, Pneumonia, Septic shock, Malignant neoplasm progression, Colitis, |
||||
PEMBROLIZUMAB, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, |
||||
| 224 | 25095930 |
ES |
47 | 2 |
Metastases to spine, Malignant neoplasm progression, Spinal cord compression, Asthenia, Paraplegia, Hypercalcaemia of malignancy, Diarrhoea, Off label use, |
||||
TUCATINIB, TRASTUZUMAB, CAPECITABINE, |
||||
| 225 | 25096072 |
73 | 2 | |
Bone cancer, Malignant neoplasm progression, |
||||
CAPECITABINE, CAPECITABINE, |
||||
| 226 | 25096369 |
CZ |
73 | 2 |
Pleural effusion, Malignant neoplasm progression, Metastases to liver, Metastases to chest wall, Breast cancer, |
||||
EVEROLIMUS, EVEROLIMUS TABLETS, EXEMESTANE, |
||||
| 227 | 25096379 |
US |
2 | |
Anaplastic thyroid cancer, Malignant neoplasm progression, Off label use, |
||||
ENCORAFENIB, BINIMETINIB, |
||||
| 228 | 25096497 |
SE |
2 | |
Red blood cell sedimentation rate increased, Pyrexia, Liver function test abnormal, Cortisol increased, Hepatitis, Malignant neoplasm progression, |
||||
NIVOLUMAB, IPILIMUMAB, SARILUMAB, |
||||
| 229 | 25096815 |
JP |
55 | 1 |
Enterocolitis, IgA nephropathy, Malignant neoplasm progression, Febrile neutropenia, |
||||
RAMUCIRUMAB, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 230 | 25097188 |
CN |
74 | |
Metastases to liver, Metastases to lung, Malignant neoplasm progression, Decreased appetite, Diarrhoea, Mouth ulceration, Nausea, Gastrointestinal disorder, Oedema peripheral, White blood cell count decreased, Neutrophil count decreased, Blood potassium decreased, |
||||
CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, |
||||
| 231 | 25086776 |
US |
85 | 2 |
Malignant neoplasm progression, Off label use, |
||||
LENALIDOMIDE, |
||||
| 232 | 25086951 |
US |
76 | 1 |
Pneumonia, Platelet count decreased, Malignant neoplasm progression, Troponin T increased, N-terminal prohormone brain natriuretic peptide increased, Red blood cell count decreased, Haemoglobin decreased, Lymphocyte count decreased, Blood creatinine increased, |
||||
PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, CARBOPLATIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ASCORBIC ACID, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, CLOPIDOGREL, CLOPIDOGREL BISULFATE, SPIRONOLACTONE, SELENIUM, ROSUVASTATIN CALCIUM, MAGNESIUM OXIDE, FOLIC ACID, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, MONTELUKAST, FUROSEMIDE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, CEFEPIME HYDROCHLORIDE, CEFEPIME, CEFTRIAXONE, CEFTRIAXONE SODIUM, DOXYCYCLINE, DOXYCYCLINE HYCLATE, GUAIFENESIN, METHYLPREDNISOLONE, PREDNISONE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, OXYGEN, 0XYGEN, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, PSYLLIUM HUSK, LOSARTAN POTASSIUM, LOSARTAN, |
||||
| 233 | 25087256 |
CA |
51 | |
Metastases to central nervous system, Metastases to liver, Breast cancer, Malignant neoplasm progression, Drug intolerance, Hot flush, Drug ineffective, Product dose omission issue, |
||||
FULVESTRANT, FULVESTRANT, ANASTROZOLE, ANASTROZOLE TABLETS, PALBOCICLIB, EVEROLIMUS, LETROZOLE, LETROZOLE TABLETS, RUXOLITINIB, |
||||
| 234 | 25087351 |
US |
68 | 1 |
Papillary thyroid cancer, Metastases to bone, Malignant neoplasm progression, Product use in unapproved indication, |
||||
DABRAFENIB, TRAMETINIB, ZOLEDRONIC ACID, |
||||
| 235 | 25087539 |
US |
1 | |
Malignant neoplasm progression, Drug ineffective, |
||||
BELZUTIFAN, AXITINIB, |
||||
| 236 | 25087930 |
MX |
||
Malignant neoplasm progression, Off label use, |
||||
IVOSIDENIB, |
||||
| 237 | 25088057 |
JP |
76 | 1 |
Malignant neoplasm progression, |
||||
EPCORITAMAB-BYSP, |
||||
| 238 | 25088087 |
JP |
68 | 1 |
Malignant neoplasm progression, |
||||
EPCORITAMAB-BYSP, |
||||
| 239 | 25088112 |
JP |
69 | 1 |
Malignant neoplasm progression, |
||||
EPCORITAMAB-BYSP, |
||||
| 240 | 25088620 |
US |
42 | 2 |
Febrile neutropenia, Malignant neoplasm progression, Drug ineffective, Product use in unapproved indication, |
||||
CAPECITABINE, CAPECITABINE, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, |
||||
| 241 | 25089161 |
CH |
||
Malignant neoplasm progression, Therapy partial responder, Insurance issue, |
||||
TAGRAXOFUSP, |
||||
| 242 | 25089469 |
CA |
2 | |
Colon cancer, Hydronephrosis, Ovarian cancer, Malignant neoplasm progression, Off label use, |
||||
LETROZOLE, LETROZOLE TABLETS, |
||||
| 243 | 25089487 |
JP |
72 | 1 |
Malignant neoplasm progression, |
||||
ZOLBETUXIMAB, FLUOROURACIL, OXALIPLATIN, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, |
||||
| 244 | 25089526 |
AT |
||
Malignant neoplasm progression, Fatigue, Polyneuropathy, Drug ineffective, |
||||
IVOSIDENIB, FLUOROURACIL, OXALIPLATIN, |
||||
| 245 | 25089699 |
US |
2 | |
Malignant neoplasm progression, Rheumatic disorder, Autoimmune disorder, Arthritis, |
||||
PEMBROLIZUMAB, |
||||
| 246 | 25089774 |
ES |
50 | 1 |
Diverticulum intestinal, Cervical spinal stenosis, Hypertrophy, Malignant neoplasm progression, Abdominal distension, Abdominal distension, Flank pain, Nerve compression, Mucosal toxicity, Diarrhoea, Mucosal inflammation, Mouth ulceration, Headache, Dizziness, Hypertension, Neuralgia, |
||||
EVEROLIMUS, EVEROLIMUS TABLETS, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, LENVATINIB, |
||||
| 247 | 25089800 |
JP |
8 | 2 |
Malignant neoplasm progression, Drug ineffective, |
||||
PEMBROLIZUMAB, OXALIPLATIN, CAPECITABINE, |
||||
| 248 | 25089803 |
JP |
74 | 2 |
Malignant neoplasm progression, Immune-mediated hepatic disorder, |
||||
PEMBROLIZUMAB, |
||||
| 249 | 25089826 |
JP |
87 | 1 |
Malignant neoplasm progression, Product storage error, |
||||
ENZALUTAMIDE, |
||||
| 250 | 25090148 |
AR |
52 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, Spinal cord disorder, Fatigue, Bradykinesia, Blood pressure abnormal, Inflammation, Full blood count abnormal, Arthralgia, White blood cell count decreased, Blood pressure increased, Joint swelling, Dysphonia, |
||||
RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, PREGABALIN, FOLIC ACID, CLONAZEPAM, |
||||
| 251 | 25090214 |
|||
Myelofibrosis, Malignant neoplasm progression, |
||||
RUXOLITINIB, |
||||
| 252 | 25090222 |
JP |
48 | 1 |
Death, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, CAPECITABINE, OXALIPLATIN, |
||||
| 253 | 25090382 |
CH |
32 | 1 |
Malignant neoplasm progression, Anal fissure, Haemorrhoidal haemorrhage, Mucosal inflammation, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 254 | 25090450 |
US |
80 | 1 |
Colon cancer metastatic, Malignant neoplasm progression, |
||||
ENCORAFENIB, |
||||
| 255 | 25091052 |
PL |
39 | 1 |
Neutropenia, Tumour lysis syndrome, COVID-19, Rash macular, Follicular lymphoma, Malignant neoplasm progression, |
||||
RITUXIMAB, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, OBINUTUZUMAB, MOSUNETUZUMAB, MOSUNETUZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CYTARABINE, CISPLATIN, |
||||
| 256 | 25092031 |
US |
81 | 2 |
Malignant neoplasm progression, Hypophagia, Micrographic skin surgery, |
||||
PANCRELIPASE, ETANERCEPT, TICAGRELOR, LOSARTAN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, GABAPENTIN, LEVOTHYROXINE, |
||||
| 257 | 25094760 |
87 | 2 | |
Diabetic ketoacidosis, Hypotension, Tachycardia, Acute kidney injury, Dehydration, Hypovolaemia, Malignant neoplasm progression, |
||||
CAPIVASERTIB, |
||||
| 258 | 25081828 |
JP |
6 | 2 |
Malignant neoplasm progression, Bone pain, Rash, Diarrhoea, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 259 | 25081852 |
TW |
66 | 1 |
Malignant neoplasm progression, |
||||
ENZALUTAMIDE, |
||||
| 260 | 25082102 |
PL |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 261 | 25082834 |
DE |
80 | 1 |
Malignant neoplasm progression, Drug ineffective for unapproved indication, |
||||
AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, |
||||
| 262 | 25083301 |
JP |
67 | 2 |
Macular oedema, Visual acuity reduced, Malignant neoplasm progression, Neutrophil count decreased, |
||||
PACLITAXEL, PACLITAXEL, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, URSODIOL, URSOSIOL, DENOSUMAB, ACYCLOVIR, VONOPRAZAN FUMARATE, |
||||
| 263 | 25084429 |
56 | 2 | |
Breast cancer female, Malignant neoplasm progression, Metastases to spine, |
||||
ABEMACICLIB, PALBOCICLIB, ADALIMUMAB, |
||||
| 264 | 25084471 |
JP |
69 | 2 |
Death, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, OXALIPLATIN, |
||||
| 265 | 25084917 |
JP |
2 | |
Malignant neoplasm progression, |
||||
LENVATINIB, PEMBROLIZUMAB, |
||||
| 266 | 25085151 |
JP |
76 | 1 |
Cytopenia, Malignant neoplasm progression, Stomatitis, Tinnitus, |
||||
PEMBROLIZUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, CISPLATIN, CISPLATIN, |
||||
| 267 | 25085819 |
ES |
1 | |
Malignant neoplasm progression, |
||||
PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, PEMBROLIZUMAB, PEMBROLIZUMAB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, MIRTAZAPINE, APIXABAN, ALPRAZOLAM, |
||||
| 268 | 25085888 |
JP |
80 | 1 |
Hypocalcaemia, Malaise, Asthenia, Trousseau^s sign, Hypophosphataemia, Blood parathyroid hormone increased, Renal failure, Anaemia, Metastases to bone, Malignant neoplasm progression, Renal tubular acidosis, Renal impairment, Dosage not adjusted, |
||||
ZOLEDRONIC ACID, BICALUTAMIDE, GOSERELIN, |
||||
| 269 | 25085946 |
JP |
7 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 270 | 25086077 |
US |
58 | 2 |
Malignant neoplasm progression, |
||||
PALBOCICLIB, |
||||
| 271 | 25086117 |
US |
70 | 2 |
Malignant neoplasm progression, |
||||
CRIZOTINIB, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, OLANZAPINE, INSULIN GLARGINE, CARVEDILOL, EZETIMIBE, ROSUVASTATIN, LEVOTHYROXINE, |
||||
| 272 | 25086324 |
JP |
52 | 1 |
Malignant neoplasm progression, Colon cancer, Cerebral haemorrhage, |
||||
ENCORAFENIB, BINIMETINIB, CETUXIMAB, |
||||
| 273 | 25086370 |
JP |
65 | 1 |
Malignant neoplasm progression, Cytokine release syndrome, |
||||
CETUXIMAB, PACLITAXEL, NIVOLUMAB, |
||||
| 274 | 25081333 |
DE |
1 | |
Malignant neoplasm progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, ABIRATERONE ACETATE, ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, |
||||
| 275 | 25081408 |
DE |
1 | |
Malignant neoplasm progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, ABIRATERONE ACETATE, ABIRATERONE, ENZALUTAMIDE, |
||||
| 276 | 25081410 |
DE |
1 | |
Malignant neoplasm progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, ABIRATERONE ACETATE, ABIRATERONE, |
||||
| 277 | 25081678 |
GB |
2 | |
Malignant neoplasm progression, |
||||
FULVESTRANT, DENOSUMAB, PREGABALIN, |
||||
| 278 | 25084184 |
1 | ||
Constipation, Urinary retention, Malignant neoplasm progression, |
||||
DAROLUTAMIDE, |
||||
| 279 | 25084212 |
71 | 2 | |
Breast cancer, Malignant neoplasm progression, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 280 | 25081126 |
RU |
2 | |
Hepatic vein thrombosis, Hepatic infarction, Malignant neoplasm progression, Hepatic cyst, Haemangioma of bone, Haemosiderosis, Blood chromogranin A increased, Biliary tract disorder, Gallbladder disorder, |
||||
LANREOTIDE ACETATE, EVEROLIMUS, EVEROLIMUS TABLETS, ACETYLCYSTEINE, OCTREOTIDE ACETATE, OCTREOTIDE, |
||||
| 281 | 25076920 |
JP |
74 | 1 |
Malignant neoplasm progression, Diarrhoea, Immune-mediated hepatic disorder, |
||||
PEMBROLIZUMAB, |
||||
| 282 | 25077240 |
JP |
1 | |
Neuroendocrine tumour, Malignant neoplasm progression, |
||||
LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, |
||||
| 283 | 25077336 |
JP |
84 | 1 |
Malignant neoplasm progression, Immune-mediated myocarditis, Immune-mediated myasthenia gravis, Renal impairment, Liver function test increased, |
||||
PEMBROLIZUMAB, AMLODIPINE BESYLATE, |
||||
| 284 | 25077774 |
JP |
52 | 2 |
Hypothyroidism, Myalgia, Stomatitis, Malaise, Thrombocytopenia, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 285 | 25078048 |
PL |
61 | 2 |
Hyperthyroidism, Malignant neoplasm progression, Immune-mediated hepatic disorder, |
||||
CARBOPLATIN, NIVOLUMAB, IPILIMUMAB, PACLITAXEL, |
||||
| 286 | 25078064 |
ZA |
70 | 1 |
Metastatic renal cell carcinoma, Malignant neoplasm progression, Off label use, |
||||
PAZOPANIB HYDROCHLORIDE, |
||||
| 287 | 25078124 |
ES |
7 | 1 |
Anaemia, Thrombocytopenia, Hepatotoxicity, Drug interaction, Drug ineffective, Drug level increased, Myelosuppression, Malignant neoplasm progression, |
||||
LINEZOLID, LINEZOLID, LINEZOLID, MIRTAZAPINE, PACLITAXEL, VINORELBINE, CARBOPLATIN, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, TRIMETHOPRIM, LINEZOLID, LINEZOLID, LINEZOLID, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, APIXABAN, ALPRAZOLAM, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, CEFTRIAXONE, CEFTRIAXONE SODIUM, AMIKACIN, |
||||
| 288 | 25078133 |
BE |
2 | |
Malignant neoplasm progression, |
||||
CARBOPLATIN, PACLITAXEL, DURVALUMAB, |
||||
| 289 | 25078437 |
US |
78 | 2 |
Malignant neoplasm progression, |
||||
PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, |
||||
| 290 | 25078927 |
DE |
60 | 2 |
Neuropathy peripheral, Malignant neoplasm progression, Proteinuria, Therapy partial responder, |
||||
RAMUCIRUMAB, PEMBROLIZUMAB, FLUOROURACIL, PACLITAXEL, |
||||
| 291 | 25079065 |
JP |
74 | 2 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 292 | 25079097 |
JP |
67 | 1 |
Hypothyroidism, Malaise, Malignant neoplasm progression, Pathological fracture, Therapy partial responder, |
||||
PEMBROLIZUMAB, |
||||
| 293 | 25079336 |
JP |
58 | 2 |
Malignant neoplasm progression, Ureteritis, Cholangitis sclerosing, Immune-mediated hepatitis, Back pain, Drug ineffective, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 294 | 25079456 |
IN |
63 | 2 |
Hormone receptor positive breast cancer, Malignant neoplasm progression, Abdominal hernia, Pain in extremity, Chest pain, |
||||
EXEMESTANE, EXEMESTANE, EXEMESTANE, |
||||
| 295 | 25079465 |
TN |
70 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, Neutropenia, |
||||
PALBOCICLIB, |
||||
| 296 | 25079485 |
FR |
77 | 2 |
Plasma cell myeloma, Malignant neoplasm progression, |
||||
ELRANATAMAB-BCMM, |
||||
| 297 | 25079491 |
JP |
53 | 2 |
Colon cancer, Malignant neoplasm progression, Interstitial lung disease, Liver disorder, |
||||
ENCORAFENIB, BINIMETINIB, CETUXIMAB, |
||||
| 298 | 25079492 |
LV |
53 | 2 |
Metastases to liver, Metastases to lung, Malignant neoplasm progression, Troponin increased, Tachycardia, Blood cholesterol increased, High density lipoprotein increased, Non-high-density lipoprotein cholesterol increased, Low density lipoprotein increased, Myalgia, Arthralgia, Chest pain, |
||||
LORLATINIB, |
||||
| 299 | 25079772 |
FR |
69 | 2 |
Neutropenia, Malignant neoplasm progression, Diarrhoea, Visual impairment, Oedema, Hypertension, Oedema peripheral, |
||||
SELPERCATINIB, GEMCITABINE HYDROCHLORIDE, PEMETREXED, PEMETREXED DISODIUM, CABOZANTINIB, OSIMERTINIB, OSIMERTINIB, TRAMETINIB, CARBOPLATIN, |
||||
| 300 | 25080238 |
JP |
74 | 2 |
Dermatitis psoriasiform, Blood corticotrophin increased, Hypokalaemia, Hypomagnesaemia, Myelosuppression, Hypocalcaemia, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28